Yahoo · Nov 10, 2026
VC funding in Europe falls short at early-stage investment hurdles
As larger late-stage funding gets a boost, biotechs struggle to secure Series A rounds to progress towards clinical development.
NASDAQ · OVID
Healthcare · Biotechnology
$2.40
Down-$0.14 (-5.51%)
Updated Nov 17, 2026, 2:38 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · OVID
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 16, 2026
OVID closed at $2.40 after 21 trading sessions, up 10.60% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 16, 2026 | $2.52 | $2.655 | $2.37 | $2.40 | 2.8M |
| Nov 13, 2026 | $2.50 | $2.555 | $2.33 | $2.54 | 2.9M |
| Nov 12, 2026 | $2.77 | $2.77 | $2.51 | $2.55 | 2.92M |
| Nov 11, 2026 | $2.80 | $2.86 | $2.66 | $2.78 | 1.82M |
| Nov 10, 2026 | $2.76 | $2.87 | $2.64 | $2.80 | 2.31M |
| Nov 9, 2026 | $2.89 | $3.09 | $2.83 | $2.85 | 6.22M |
| Nov 6, 2026 | $2.56 | $2.945 | $2.5585 | $2.85 | 3.9M |
| Nov 5, 2026 | $2.74 | $2.7499 | $2.485 | $2.58 | 2.02M |
| Nov 4, 2026 | $2.50 | $2.79 | $2.375 | $2.74 | 3.61M |
| Nov 3, 2026 | $2.39 | $2.495 | $2.38 | $2.40 | 1.38M |
| Nov 2, 2026 | $2.55 | $2.60 | $2.37 | $2.39 | 2.34M |
| Oct 30, 2026 | $2.51 | $2.70 | $2.44 | $2.54 | 3.15M |
| Oct 29, 2026 | $2.45 | $2.58 | $2.405 | $2.56 | 2.04M |
| Oct 28, 2026 | $2.26 | $2.495 | $2.205 | $2.45 | 2.06M |
| Oct 27, 2026 | $2.18 | $2.28 | $2.10 | $2.26 | 1.69M |
| Oct 26, 2026 | $2.19 | $2.22 | $2.1213 | $2.155 | 844.07K |
| Oct 23, 2026 | $2.31 | $2.32 | $2.12 | $2.16 | 2.02M |
| Oct 22, 2026 | $2.45 | $2.50 | $2.34 | $2.37 | 1.18M |
| Oct 21, 2026 | $2.37 | $2.65 | $2.345 | $2.47 | 5.01M |
| Oct 20, 2026 | $2.19 | $2.46 | $2.175 | $2.36 | 3.67M |
| Oct 19, 2026 | $2.18 | $2.225 | $2.14 | $2.17 | 1.64M |
The latest Smart Investors Daily articles mentioning OVID.
Company
Market Activity
Research & News
OVID research
Company profile and research snapshot.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 15, 2026 | Wolfe Research | Outperform | — |
| Oct 9, 2026 | Cantor Fitzgerald | Overweight | — |
| Oct 6, 2026 | Guggenheim | Buy | — |
| Oct 5, 2026 | Guggenheim | Buy | — |
| Sep 11, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Nov 10, 2026
As larger late-stage funding gets a boost, biotechs struggle to secure Series A rounds to progress towards clinical development.
Yahoo · Nov 10, 2026
OV329 is advancing in a global, Phase 2 focal epilepsy study expected to read out in H2 2027Ovid is enrolling patients in ongoing photosensitivity study intended to demonstrate the anticonvulsant effect of OV329; results expected in early 2027OV4071, the first-ever oral KCC2 direct activator, continues to progress in a Phase 1 single- and multiple-ascending dose study; translational ketamine challenge study ready for initiationAdvancement of a pediatric formulation of OV329 is on track and Compa
Benzinga · Nov 10, 2026
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 41.18 percent increase over losses of $(0.17) per share
Yahoo · Nov 6, 2026
Anika (ANIK) delivered earnings and revenue surprises of +70.59% and +3.94%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning OVID.